-

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of January:

  • Goldman Sachs Annual Healthcare CEOs Unscripted Conference: A View from the Top on Thursday, January 4, 2024 at 9:30 am (EST)

  • 42nd Annual J. P. Morgan Healthcare Conference on Monday, January 8, 2024 at 7:30 am (PST)

The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Contacts

Media
media@incyte.com

Investors
ir@incyte.com

Industry:

Incyte

NASDAQ:INCY
Release Versions
English

Contacts

Media
media@incyte.com

Investors
ir@incyte.com

More News From Incyte

Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis

WILMINGTON, Del.--(BUSINESS WIRE)--Update on FDA Review of Ruxolitinib Cream (Opzelura) for Children Ages 2-11 with Atopic Dermatitis...

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). "Patients living with relapsed or refractory FL have been waiting for new options that improve progression-free survival without...

Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

WILMINGTON, Del.--(BUSINESS WIRE)--Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025...
Back to Newsroom